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The autoimmune model of multiple sclerosis (MS)
pathogenesis provided for many years a useful but in-
complete conceptual framework for understanding the
complex array of factors that lead to the loss of im-
mune homeostasis, myelin and axonal injury, and pro-
gressive neurological symptoms. The availability of
novel tools in molecular neurogenetics and increas-
ingly sophisticated neuroimaging technologies, to-
gether with the revitalization of MS neuropathology,
has created a new paradigm for the multidisciplinary
study of this disease. This is reflected by the growing
resolution of the MS genomic map, discovery of deli-
cate inflammatory networks that are perturbed in MS,
identification of mediators of demyelination, and rec-
ognition that cumulative axonal loss and neuronal in-
jury are the histological correlates of neurological dis-
ability. Together, these advances have set the stage
for the development of therapeutic approaches de-
signed to target the demyelinating and neurodegener-
ative components of the disease and promote repair.
Introduction
Multiple sclerosis (MS), the most common cause of
chronic neurologic disability beginning in early to middle
adult life, has in recent years emerged as a subject of
considerable interest to the neuroscience community.
The global burden of MS has a number of truly remark-
able characteristics, including an increasing incidence
over the past century, an influence of latitude on risk,
and increased risk in both females and white popula-
tions, especially those of northern European ancestry.
Tracing the historical roots of MS has proven to be diffi-
cult, given the lack of knowledge of clinical-anatomic lo-
calization in neurology prior to the late 19th century.
Notable is the paucity of convincing MS-like illnesses
in the historical record prior to this time. Two reports
from the late 13th century described women afflicted
with chronic, multifocal, and partially remitting neuro-
logic illnesses that conceivably might have been MS;
these were the cases of a woman named Halla con-
tained in the Icelandic Saga of St. Thorklar (Poser,
1994) and of a Dutch woman named Lidwina van Schie-
dam (Medaer, 1979). These uncertain cases excepted,
MS makes its first clear appearance in 1822 in the diaries
of Augustus D’Este, the illegitimate grandson of King
George III (Firth, 1948).
Although it is not known whether MS is indeed
a ‘‘new’’ disease, studies of the prevalence of MS con-
ducted in multiple regions of the world suggest that
the incidence increased steadily during the 20th century.
*Correspondence: jorge.oksenberg@ucsf.eduIt is possible that some of this increase is an artifact of
improved case ascertainment, but most investigators
believe that it is, at least in part, real, suggesting the
presence of new environmental triggers. For many years
multiple sclerosis was considered an immune-mediated
disorder, primarily of interest to immunologists. How-
ever, the situation changed in the mid-1990s with the
recognition that a neurodegenerative process, unre-
sponsive to immunosuppression, was responsible for
progressive neurological impairment. This new informa-
tion, largely derived from results of clinical trials and re-
assessment of the neuropathology of MS, has brought
myelin biology to the forefront of MS research. It empha-
sizes the need to understand, in the context of this dis-
ease, the axonal changes that follow demyelination,
axon-myelin interactions essential to normal neuronal
function and survival, and oligodendrocyte differentia-
tion and remyelination.
This review builds on both well-established and
emerging concepts of pathogenesis and their relation-
ship to therapy, and the focus is on three core themes
underlying the disease process: genes, inflammation,
and neurodegeneration. No brief review of MS can fully
address the breadth of issues related to this complex
and multifactorial disease, and for more detail a number
of outstanding sources exist (see for example Waxman,
2005 and Compston et al., 2006). The current challenges
for the MS research community are to integrate large
volumes of data from multiple sources to develop im-
proved models of pathogenesis, and to translate these
into effective therapies for the two million affected indi-
viduals worldwide.
Clinical Features
Symptoms of MS result from interruption of myelinated
tracts in the central nervous system (CNS); the periph-
eral nervous system is spared. Initial symptoms are
commonly one or more of the following: weakness or di-
minished dexterity in one or more limbs, a sensory dis-
turbance, monocular visual loss (optic neuritis), double
vision (diplopia), gait instability, and ataxia. Onset may
be abrupt or insidious, and early symptoms may be se-
vere or seem so trivial that a patient may not seek med-
ical attention for months or years. As the disease
worsens, bladder dysfunction, fatigue, and heat sensi-
tivity occurs in most patients. Ancillary symptoms in-
clude Lhermitte’s symptom (an electric shock-like sen-
sation down the spine and into the limbs evoked by
neck flexion), hemifacial weakness or pain, vertigo,
and brief tonic spasms and other paroxysmal symptoms
(thought to represent discharges originating along de-
myelinated axons). Cognitive deficits are common, es-
pecially in advanced cases, and include memory loss,
impaired attention, problem-solving difficulties, slowed
information processing, and difficulties in shifting be-
tween cognitive tasks. Depression is experienced
by w60% of patients during the course of the illness,
and suicide is 7.5-fold more common than in age-
matched controls.
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62Figure 1. MRI Images in MS
(A) Axial first-echo image from T2-weighted
sequence demonstrates multiple bright sig-
nal abnormalities in white matter, typical for
MS.
(B) Sagittal T2-weighted fluid attenuated in-
version recovery (FLAIR) image in which the
high signal of CSF has been suppressed.
CSF appears dark, while areas of brain
edema or demyelination appear high in signal
as shown here in the corpus callosum (ar-
rows). Lesions in the anterior corpus cal-
losum are frequent in MS and rare in vascular
disease.
(C) Sagittal T2-weighted fast spin echo image
of the thoracic spine demonstrates a fusiform
high-signal-intensity lesion in the mid tho-
racic spinal cord.
(D) Sagittal T1-weighted image obtained after
the intravenous administration of gadolinium
DTPA reveals focal areas of blood-brain
barrier disruption, identified as high-signal-
intensity regions (arrows).The diagnosis of MS has been revolutionized by mag-
netic resonance imaging (MRI) technology, which re-
veals multiple, asymmetrically located white matter le-
sions distributed throughout the white matter of the
CNS, with a predilection for the corpus callosum and
deep periventricular regions (Figure 1). New lesions are
heralded by breakdown of the blood-brain barrier asso-
ciated with perivenous inflammation and detected by
extrusion of the heavy metal gadolinium across the
blood-brain barrier. Spinal cord lesions are frequently
present and can be detected with high sensitivity using
high-field MRI. Ancillary tests, used primarily in uncer-
tain or problematic cases, consist of cerebrospinal fluid
(CSF) studies revealing low levels of inflammation with
mononuclear cells (generally <50 cells/mm3) and raised
levels of immunoglobulin, including antibodies with re-
stricted clonotypes (oligoclonal bands). Evoked poten-
tials in the visual, auditory, or sensory pathways may
also be helpful in identifying additional, silent lesions
(Hauser and Goodin, 2005).
Although early microscopic studies reported demye-
lination in the cerebral cortex of affected brains (Brow-
nell and Hughes, 1962), MS is generally perceived as
a white matter disease. There is, however, an increasing
interest in the involvement of gray matter in MS, and
some observers believe that cortical plaques are impor-
tant contributors to motor, sensory, and cognitive dis-
ability in MS (Kidd et al., 1999; Peterson et al., 2001).
Cortical demyelination appears to be very rare in acute
or early relapsing MS and reduction of cortical thickness
is seen primarily in patients with long-standing disease
(Bozzali et al., 2002), suggesting that cortical pathology
follows the white matter disease (Kutzelnigg et al., 2005).Microglia activation and diffuse axonal injury are typi-
cally associated with active lesions in the cortex, but
the classical perivascular lymphocytic infiltration char-
acteristic of the white matter plaques is absent (Bo
et al., 2003; Peterson et al., 2001; Kutzelnigg et al.,
2005). Overall, there is an emerging consensus that cor-
tical lesions and atrophy are major contributors to dis-
ease burden in patients with MS. The development of
novel animal models displaying demyelinating lesions
in the cortex (Merkler et al., 2006) will be of great value
to fully assess the role of cortical pathology in MS.
The Basis of Neurological Disability
Although MS can vary from a benign illness to a rapidly
evolving and incapacitating disease, most patients with
MS ultimately experience progressive disability. Ap-
proximately 85% of all MS patients manifest initially as
recurrent attacks of neurologic dysfunction (relapses);
these occur 1–2 times annually and, especially in the
early phases, are typically followed by gradual improve-
ment (remissions) over several months. Women are
affected with relapsing-remitting MS twice as frequently
as men. Approximately 15% of patients begin with
a purely progressive course, termed primary progres-
sive MS; interestingly, these patients tend to be older
than relapsing-onset patients and are male as often as
female.
MS relapses are associated with the development of
new, focal, and usually permanent MRI lesions. These
areas of altered signal intensity, once established, re-
flect fluid shifts due to a combination of demyelination
and gliosis. Serial studies in relapsing MS indicate that
approximately six out of seven newly formed MRI
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63lesions are clinically silent. Furthermore, even symptom-
atic lesions do not in most cases produce permanent
disability, as remissions are the rule, especially early in
the disease course, and the correlation between the to-
tal lesion load detectible by MRI and concurrent disabil-
ity is weak (Goodin, 2006). Nevertheless, the develop-
ment of a large number and volume of lesions during
the initial years of MS is strongly associated with
a greater risk of disability occurring years later (Brex
et al., 2002; Rudick et al., 2006). There is a widely circu-
lated aphorism in the field that a relapse in 2006 may
produce disability in 2016. This thinking has led to the
widespread application of anti-inflammatory disease-
modifying therapies for MS, largely in the hope that
reduction in the accumulation of focal lesions not only
decreases relapses but might also lessen late neurode-
generation and ultimate neurologic disability.
Disability in MS is not due primarily to the effects of re-
lapses, but results from chronic progressive worsening,
usually manifested as progressive spastic weakness of
the limbs. For patients with relapsing-onset MS, the
risk of transitioning from a relapsing to a progressive
course is relatively linear and approximately 2.5% annu-
ally. Fifteen years after diagnosis, fewer than 20% of pa-
tients with MS have no functional limitation, 50% to 60%
require assistance when ambulating, 70% are limited or
unable to perform major activities of daily living, and
75% are not employed. In a recently published natural
history study, females reached disability endpoints at
an older age than males (Confavreux and Vukusic,
2006a). However, the most important clinical factor influ-
encing progression to disability was age at clinical on-
set: the younger the onset, the younger the age achiev-
ing the disability milestones. In contrast, no other
variables, including relapsing or progressive course,
substantially affected the time to reach severe disability
(Confavreux et al., 2003; Confavreux and Vukusic,
2006b). Furthermore, times from clinical onset to
a Kurtzke Expanded Disability Status Scale (EDSS)
score of 6 (walking with unilateral aid) and 7 (wheelchair
bound) were primarily influenced by the time the patient
reached a score of 4 (limited walking but without aid). In
contrast, no other variables had a measurable influence
on the time elapsed from a score of 4 to a score of 6 or 7,
or from a score of 6 to a score of 7. These observations
suggest that once a certain pathologic threshold is
reached, most patients with MS progress along a com-
mon irreversible neurodegenerative pathway.
Despite important advances in therapeutics for MS,
none of the currently available disease-modifying drugs
have yet been shown to significantly alter the long-term
natural history of the disease (Feldmann and Steinman,
2005; Hohlfeld and Wekerle, 2004; Noseworthy, 2003).
Further, the partial, negligible, or deleterious effects
that some approaches have yielded in the clinic, despite
being successful at the bench, reflect the complex mo-
lecular interactions operating in MS and the limitations
of current working hypotheses as faithful models of
disease pathogenesis. These models support the occur-
rence of two overlapping and connected arms, inflam-
matory and neurodegenerative (Figure 2). Any satisfac-
tory understanding of the biology of MS must explain
the temporal relationship between these two phases of
MS (Figure 3).Genetic Susceptibility
MS clusters with the so-called complex genetic dis-
eases, a group of common disorders characterized by
modest disease risk heritability and multifaceted gene-
environment interactions. The genetic component in
MS is primarily suggested by familial aggregation of
cases and the high incidence in some ethnic populations
(particularly those of northern European origin) com-
pared with others (African and Asian groups), irrespec-
tive of geographic location. High frequency rates are
found in Scandinavia, Iceland, the British Isles, and
North America (about 1–2 in 1,000). Lower frequencies
are found among southern Europeans. The disease is
uncommon among Samis, Turkmen, Uzbeks, Kazakhs,
Kyrgyzis, native Siberians, North and South Amerin-
dians, Chinese, Japanese, African blacks, and New Zea-
land Maori (Rosati, 2001). According to some observers,
this characteristic geographical distribution implicates
a pathogen that is not ubiquitously distributed (see be-
low). However, this prevalence pattern can also be ex-
plained, at least in part, by the geographical clustering
of northern Europeans and their descendants (Sotgiu
et al., 2003).
Evidence of risk heritability in the form of familial re-
currence has long been known. The degree of familial
aggregation can be determined by estimating the ratio
of the prevalence in siblings versus the population
Figure 2. Natural History of MS
Four clinical patterns are recognized by international consensus.
Approximately 85% of patients experience relapsing-remitting MS
(RR-MS), characterized by the abrupt start of symptoms and acute
episodes of worsening (exacerbations or relapses) with complete
or partial recovery. Between these episodes, patients may be clini-
cally stable, may experience gradual progression of disability, or
may undergo a combination of both. Approximately 50% of patients
with RR-MS convert to secondary progressive MS (SP-MS) within 10
years of disease onset. The secondary progressive phase is charac-
terized by gradual progression of disability with or without superim-
posed relapses. In contrast, patients with primary progressive MS
(PP-MS, approximately 10% of patients with MS) experience grad-
ual progression of disability from onset without superimposed re-
lapses. Patients with progressive relapsing MS experience gradual
progression of disability from disease onset, later accompanied by
one or more relapses; this clinical pattern affectsw5% of patients.
An important conceptual development in the understanding of MS
pathogenesis has been the compartmentalization of the mechanis-
tic process into two distinct but overlapping and connected phases,
inflammatory and neurodegenerative. Axonal loss begins most likely
at disease onset and accumulates. Conversion of relapsing-remit-
ting to secondary progressive occurs once axon loss surpasses
the capacity of the CNS to compensate for loss of function.
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64Figure 3. Models of Disease Pathogenesis in MS
The traditional neuropathological view of MS (A) highlights CNS injury as a consequence of an autoimmune response. An alternative hypothesis
(B) proposes that activation of autoimmune cells occurs as a consequence of toxic insults to CNS cells. Infections, for example, may be asymp-
tomatic but cause cytophatic effects to target cells in the course of an antiviral response. The prolonged release of neural antigens may then
induce inflammatory responses.prevalence of the disease (ls). For MS, the ls ranges be-
tween 20 (0.02/0.001) and 40 (0.04/0.001). Half-sibling
(Sadovnick et al., 1996), adoptee (Ebers et al., 1995),
spouse (Ebers et al., 2000), and risk assessment studies
performed in Canada appear to confirm that genetic,
and not environmental, factors are primarily responsible
for the familial clustering of cases. However, an intrigu-
ing association with month of birth was observed in
the Canadian familial cases, reflecting perhaps an inter-
action between genes and an environmental factor op-
erating during gestation or shortly after birth (Willer
et al., 2005). Concordant sibs tend to share age of symp-
tom onset rather than year of onset, supporting a genetic
effect on the familial recurrence. Concordance in fami-
lies for early and late clinical features has been observed
as well, suggesting that in addition to susceptibility,
genes may influence disease severity or other aspects
of the clinical phenotype (Barcellos et al., 2002; Brassat
et al., 1999; Kantarci et al., 2002). Twin studies from dif-
ferent populations consistently indicate pairwise con-
cordance (20%–30% in identical twin pairs compared
to 2%–5% in like-sex fraternal twin pairs), providing ad-
ditional evidence for a genetic etiology in MS. Overall,
neither the recurrence familial rate nor the twin concor-
dance supports the presence of a Mendelian trait.
Modeling the available data predicts that the MS-prone
genotype results from multiple interacting polymorphic
genes, each exerting a small or at most a moderate
effect to the overall risk. Their incomplete penetrance
and moderate individual effect probably reflects epi-
static interactions and postgenomic events; these
may include genes that rearrange somatically to
encode a vast variety of immune receptors, posttran-
scriptional regulatory mechanisms, and incorporation
of retroviral sequences. An additional layer of difficultyis encountered when genetic heterogeneity is consid-
ered, whereby specific genes or alleles influence sus-
ceptibility and pathogenesis in some affected individ-
uals, but not in others.
The HLA-DRB1 gene on chromosome 6p21 is the
strongest genetic factor identified as influencing MS
susceptibility (Figure 4). The association of MS with
HLA genes, specifically the DRB1*1501 allele, has
been a consistent finding across nearly all populations
(Oksenberg and Barcellos, 2005). Recent studies sug-
gest the possibility that complex trans HLA-DRB1 allelic
interactions may determine the balance between sus-
ceptibility and resistance (Barcellos et al., 2003, 2006;
Dyment et al., 2005). For example, there is a DRB1*15
dose effect on susceptibility, and the DRB1*15/08 and
DRB1*15/14 genotypes are high risk and protective, re-
spectively. The exact mechanism(s) by which the DRB1
gene influences susceptibility to MS remain undefined,
but are likely related to the physiological function of
HLA molecules in immune responses, including antigen
binding and presentation, and T cell repertoire determi-
nation by negative selection of high-avidity autoreactive
T cells within the embryonic thymic microenvironment
(Stratmann et al., 2003; Wucherpfennig, 2005). Although
a recent high-density single nucletoide polymorphism
(SNP) study covering the MHC region assigns the entire
association signal to the HLA class II region (Lincoln
et al., 2005), the debate concerning the role of non-
HLA class II genes mapping to this region continues,
with some data suggesting that additional disease
genes lie within the central class III and/or telomeric to
the class I HLA regions.
The identification of the true predisposing gene or
genes within the HLA region has been held back by
the extensive linkage disequilibrium (LD) across the
Review
65Figure 4. The 6p21-23 Chromosomal Region and MS
The full sequence of the MHC region was completed and reported in 1999. From 224 identified loci, 128 are predicted to be expressed and about
40% are predicted to have immune response functions. The diagram shows the relative positions of class I and II loci involved in antigen presen-
tation. Other genes mapped in the MHC region include complement proteins, genes for the steroid 21-hydroxylase, tumor necrosis factor, and heat-
shock proteins, collectively known as class III. The locus contains at least one gene (HLA-DRB1) influencing susceptibility to multiple sclerosis.locus (Miretti et al., 2005). LD refers to the presence of
alleles at neighboring loci segregating together at the
population level more frequently than would be ex-
pected according to the genetic distance that separates
them. LD generates long-range correlations among alle-
lic variations in the human genome, the so-called ‘‘hap-
lotype-blocks.’’ The maintenance of these blocks is
most likely due to the nonuniform distribution of recom-
bination, which tends to occur at ‘‘hot spots’’ demarcat-
ing one block from the next. The extended haplotypes
are the result of recent population history and, if com-
mon in a population, may indicate recent positive selec-
tion events. Available data show that LD extends over
greater physical distances in the MHC region than else-
where in the genome as a result of reduced recombina-
tion rate in the region, 0.44 cM/Mb, compared with a ge-
nome-wide average of 1.2 cM/Mb. Because LD patterns
differ between populations, a powerful approach to re-
solving this complex genetic obstacle will be to scruti-
nize and compare a large number of MS haplotypes in
well-characterized datasets from distinct populations.
In the case of MS, this can be accomplished by compar-
ing high-risk groups of northern European descent ver-
sus low-risk nonwhite populations. African Americans
are at a lower risk for MS when compared with northern
Europeans and white Americans (Kurtzke et al., 1979;
Wallin et al., 2004), but tend to have a more aggressive
disease course (Cree et al., 2004). In a recent study of
HLA-DRB1 and -DQB1 alleles and haplotypes in an Afri-
can-American MS cohort, a selective association with
HLA-DRB1*15 was revealed, indicating a primary rolefor the DRB1 gene in MS independent of DQB1*0602
(Oksenberg et al., 2004). It is then likely that HLA-
DRB1 constitutes the centromeric boundary of the class
II DR-DQ association in MS. African-American patients
also exhibited a high degree of allelic heterogenity as
disease association at the DRB1 locus was found for
DRB1*1501, DRB1*1503, and DRB1*0301 alleles. The
haplotypic features of the DRB1*1501-DQB1*X (non
0602) and DRB1*1503-positive chromosomes indicated
an older African origin for the HLA-associated MS sus-
ceptibility gene(s), predating the divergence of human
ethnic groups, rather than being solely due to genetic
admixture with people of European descent. HLA-
DRB1*1501 has a relative low frequency in Africa. Posi-
tive selection for this allele appears to have occurred in
Europeans, but not in Africans, and although the factors
which drove this selection, presumably some infectious
pathogen, are unknown, one possible consequence was
a heightened susceptibility to MS in Europe, a disorder
almost nonexistent in Africa.
As indicated before, compared to European Ameri-
cans, African Americans are at low risk for MS, support-
ing the presence of genetic risk factors that occur at
higher frequency in Europeans. Because the sections
of the genome in African Americans inherited from their
European or African ancestors have only had an average
of six generations of recombination, extended LD is
present in these segments, and non-MHC disease
genes are potentially amenable to identification through
admixture mapping using relatively low numbers of
ancestry-informative genetic markers (Patterson et al.,
Neuron
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on the observation that, on average, 80% of the ancestry
of African Americans is West African and about 20% is
European, and works by searching through the genome
for sections with an unusually high proportion of Euro-
pean or African ancestry compared with the average.
African Americans affected with MS will inherit a higher-
than-average proportion of African or European ances-
try, depending on which population has a higher risk
for disease at the genetic level. We have already had
successes with admixture mapping and just recently
identified a locus on chromosome 1 where there is a sig-
nificantly high proportion of European ancestry in MS
chromosomes compared with the genome-wide aver-
age and controls; followup should identify the exact
gene responsible for the admixture signal associated
with MS (Reich et al., 2005).
Unequivocal genetic linkage and association was re-
peatedly demonstrated in the HLA region. Using the el-
egant formulation of Risch (1990), it is possible to use
the values of HLA allele sharing by descent in sibships
and estimate the proportion of ls that is explained by
the HLA-DRB1 locus. Using data from 98 multicase MS
families, we estimated that the HLA region accounts
for 17%–60% of the genetic susceptibility in MS (Haines
et al., 1998). Yet even at the upper bound of this esti-
mate, much of the inheritance of MS remains unex-
plained. The lack of an obvious and homogeneous
mode of transmission has slowed progress by prevent-
ing the full exploitation of classical genetic epidemio-
logic techniques for gene discovery. Nevertheless, an
approach that dominated MS genetics until recently in-
volved first determining the chromosomal region of the
genetic effect by linkage analysis, which has been ex-
tremely productive for mapping genes responsible for
monogenic diseases. The establishment of genetic link-
age requires the collection of family pedigrees with more
than one affected member to track the inheritance of
discrete chromosomal segments that deviate from inde-
pendent segregation and cosegregate with the disease.
The potential of linkage mapping for gene identification
in complex diseases was highlighted in studies of type 2
diabetes, Crohn’s disease, and schizophrenia (Stefans-
son et al., 2002). To assess the full power of the linkage
approach and upgrade the MS genetic map, one of the
largest linkage screens ever performed in an autoim-
mune disease was recently completed by an interna-
tional consortium (Sawcer et al., 2005). Unequivocal
linkage was demonstrated in the MHC region (as ex-
pected) and suggestive linkage was identified on broad
regions of chromosomes 17, 19, and 5; fine mapping is in
progress. However, the statistical scrutiny of this map
indicates that the next generation of studies attempting
to identify the genes influencing the development of this
disease will need to rely on association methods and
large DNA collections. Genome-wide association stud-
ies harbor great potential for complex disorders, but
a number of very important challenges, including how
to interpret results obtained from large numbers of sta-
tistical tests, and how to detect biologically meaningful
interactions between polymorphisms that confer dis-
ease risk, will need to be overcome. Progress in devel-
oping affordable high-throughput genotyping technol-
ogy and a better understanding of the complexfunctional structure embedded in the human genome
suggest that the tools may finally be at hand to achieve
the elusive goal of whole-genome association studies. A
powerful trio-based study using 500,000 SNP arrays is
currently in progress by this consortium, and results
are expected by early fall. This screen will provide
a more definitive MS genetic map, but all candidate
loci will require stringent independent replication. Fur-
thermore, interpretation of genomic data must take
into account that variants of interest may result from
segmental duplications (Fredman et al., 2004), inver-
sions (Stefansson et al., 2005), loss of imprinting (Mum-
mert et al., 2005), paralogous or other regions with poly-
morphic genomic imbalances (Iafrate et al., 2004), or
genes resistant to X-inactivation (Carrel and Willard,
2005). It is also important to consider that preferential al-
lelic expression provides an additional source of vari-
ability (Lo et al., 2003b; Yan et al., 2002), and copy num-
ber polymorphisms (CNPs) contribute substantially to
normal human genomic variation for numerous genes in-
volved in neurological function, regulation of cell growth,
and regulation of metabolism (Sebat et al., 2004).
Role of the Environment
Epidemiological, clusters or outbreaks, and migration
studies have been widely used to illustrate potential en-
vironmental influences on MS. Although the interpreta-
tion of most of these studies has been difficult, in part
due to the small number of study participants in the in-
dividual reports, the results have been influential and
do suggest a role for environmental factors in MS, and
in some cases, they suggest the existence of critical
time periods for exposure to putative environmental dis-
ease agents. A large number of environmental expo-
sures have been investigated. Those include viral and
bacterial infections, nutritional and dietary factors, well
water consumption, exposure to animals, minerals,
trauma due to accident or surgery, pollution, solar radi-
ation, temperature, rainfall, humidity, chemical agents,
metals, organic solvents, and various occupational haz-
ards. Common viruses are among the most frequently
studied and biologically plausible putative infectious
agents related to MS pathogenesis, and many have
been proposed at one time or another to be the causa-
tive MS agent. Prominent candidates have included
measles, rubella, mumps, and the herpes viruses, in-
cluding Epstein Barr virus (EBV), herpes simplex virus
(HSV) 1 and 2, varicella zoster virus, and HHV6. Strong
evidence for a role of EBV in particular, a ubiquitous her-
pesvirus with a worldwide distribution, has been indi-
cated by epidemiologic (Ascherio et al., 2001) and labo-
ratory studies (Cepok et al., 2005; Levin et al., 2005). A
higher risk of infectious mononucleosis (associated
with relatively late EBV infection) and higher antibody
titers to the latency-associated antigen EBNA1 are as-
sociated with MS, and conversely, individuals never
infected by EBV are at low MS risk. No compelling mech-
anistic explanation to account for the EBV-MS relation-
ship is known.
Attempts to isolate the causative environmental trig-
ger(s) in MS have been largely unproductive and have
failed to provide breakthrough insights into mechanisms
of disease susceptibility and pathogenesis. This may be
due to heterogeneity operating also at the level of
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ent forms of the same disease in response to a common
causative agent or other trigger or whether the genotype
reflects different diseases with completely separate en-
vironmental causes is not known. The expectation that
any single agent would have enough specificity and uni-
versality to account for all cases of this disease seems
unlikely. However, it would be premature to dismiss
the possibility that a previously undetected agent could
be responsible for MS, acting either as a trigger for an
autoimmune response, or even as a chronic active
CNS infection directly responsible for symptoms.
Triggering and Persistence of Inflammation
Early in the 1930s, Rivers and others defined the labora-
tory autoimmune disease experimental allergic (or
autoimmune) encephalomyelitis (EAE) (Rivers and
Schwenker, 1935). EAE can be induced in a variety of
animal species, including nonhuman primates, by im-
munization with myelin proteins or their peptide deriva-
tives. When studied in genetically susceptible animals,
immunization induces brain inflammation accompanied
by varied signs of neurologic disease. EAE and MS share
common clinical, histologic, immunologic, and genetic
features; hence EAE is widely considered to be a relevant
model for the human disease (Steinman and Zamvil,
2006). Demonstration in the early 1960s that EAE could
be adoptively transferred by myelin-sensitized T cells in-
augurated the era of T cell immunology in MS research,
an approach that in many respects dominates the field
to this day. Although the inflammatory changes that oc-
cur in MS may ultimately be shown to be secondary
rather than primary (inflammation and selective destruc-
tion of brain elements may also occur in nonautoimmune
conditions, including genetic disorders such as adreno-
leukodystrophy or chronic virus infections such as
HTLV-1), numerous studies in blood, cerebrospinal fluid,
and brain tissues of individuals with MS have exposed
cellular and humoral immune responses against CNS
antigens that are not as prominent in non-MS controls
(Hafler et al., 2005). These studies provide the rationale
for a disease model driven by the loss of immune ho-
meostasis and uncontrolled immune responses against
structural CNS components.
During the initial state of the inflammatory response,
lymphocytes with encephalitogenic potential are acti-
vated in the periphery and home to the CNS, become
attached to receptors on endothelial cells, and then
proceed to pass across the blood-brain barrier (BBB),
through the endothelium and the subendothelial basal
lamina into the interstitial matrix. Remarkably, the pres-
ence of immunocompetent cells with autoimmune po-
tential appears to be an embedded characteristic of
the (healthy) immune system in vertebrates (Genain
et al., 1994; Hohlfeld et al., 2000). These cells may
provide important inflammatory signals necessary for
wound healing, angiogenesis, neuroprotection, and
other maintenance functions. Furthermore, CNS-spe-
cific T cells can provide neurotrophic factors such as
BDNF and contribute to the maintenance of neurogene-
sis and spatial learning abilities in adulthood (Ziv et al.,
2006). The transition from physiological to pathological
autoimmunity involves at least two factors: (1) the loss
of immune homeostasis, normally maintained throughthe induction of anergy or apoptosis, receptor downre-
gulation, editing, and anti-idiotypic/cellular regulatory
networks, and (2) the engagement and activation of lym-
phocytes by adjuvant signals including, conceivably, re-
current exposures to exogenous pathogens. This could
occur via nonspecific polyclonal activation of T and B
cells by bacterial or viral antigens, or, alternatively, as
a consequence of structural homology between a self-
protein and a protein in the pathogen, a process com-
monly referred as molecular mimicry (Steinman et al.,
2002). It is notable, for example, that components of
the myelin sheath share amino acid homologies with
proteins of measles, influenza, herpes, papilloma, and
other viruses. These pathogens acquired sufficient
homology to engage myelin-specific T cells and drive
a misguided response (Lang et al., 2002). Amino acid
identity may not even be required for cross-reactivity
to occur between the autoantigen and the mimic, as
long as they share chemical properties at critical resi-
dues that allow anchoring to antigen-presenting mole-
cules and interaction with the T cell antigen receptor.
Once activated, T cells express surface molecules
called integrins, which mediate binding to the special-
ized capillary endothelial cells of the BBB. One such in-
tegrin, VLA-4, binds the vascular cell adhesion molecule
(VCAM) expressed on capillary endothelial cells follow-
ing induction by TNF-a and IFN-g during an inflamma-
tory response. Building on successful modulation of de-
myelination in animal models with anti a4b1 integrin
antibodies (Yednock et al., 1992), clinical trials with Na-
talizumab, a humanized monoclonal antibody directed
against the a4 integrin of the adhesion molecule VLA-
4, were conducted, and very encouraging results were
reported in both MS (O’Connor et al., 2004) and Crohn’s
disease (Ghosh et al., 2003). Unfortunately, this modality
of therapy resulted in an unexpected compromise of
CNS immune surveillance mechanisms in a small num-
ber of individuals who were concomitantly treated with
immunomodulatory or immunosuppressive therapies,
resulting in progressive multifocal leukoencephalopathy
(PML) due to JC virus infection (Sheridan, 2005). At least
one affected patient was on Natalizumab monotherapy
at the time PML developed. Ransohoff (2005) proposed
that Natalizumab may activate bone marrow B cells,
which appear to serve as natural reservoir for PML virus
in the healthy adult and promote viral replication and
passage of the virus to the CNS.
As the activated T cells migrate across the BBB to
reach the CNS parenchyma, they express gelatinases
(matrix metalloproteinases, MMP) responsible for lysis
of the dense subendothelial basal lamina. The clinical
relevance of metalloproteinases is underscored by the
observation that some members of this family of mole-
cules are present in the cerebrospinal fluid of patients
with MS, but not in normal controls (Leppert et al.,
1998). TNF-a-converting enzyme (TACE, ADAM 17),
a member of the ADAM (a disintegrin and metalloprotei-
nase) family of enzymes, releases TNF-a from its cell
membrane-bound precursor by proteolytic cleavage.
In a longitudinal study of 11 relapsing-remitting MS
patients, TACE mRNA expression in peripheral blood
mononuclear cells showed a significant correlation
with the number of lesions (Seifert et al., 2002). Thus,
metalloproteinases may act not only as mediators of
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flammatory reaction through TNF processing. Further-
more, a direct neurotoxic effect for metalloproteinases
has been proposed as well; microinjection of activated
MMPs into the cortical white matter of experimental
animals results in axonal injury, even in the absence of
local inflammation (Newman et al., 2001). Beta inter-
feron, currently the most frequently employed treatment
for MS, works in part by reducing expression of MMP
by activated T lymphocytes and interfering with their
passage across the BBB (Leppert et al., 1996; Stuve
et al., 1996).
After traversing the BBB, pathogenic T cells are reac-
tivated by fragments of myelin antigens. Recent data
suggest that this is a two-step process (Platten and
Steinman, 2005). Primed CD4+ T cells are first engaged
by CD11c-expressing antigen presenting cells (APCs) in
the perivascular space before moving into the paren-
chyma. Reactivation induces additional release of proin-
flammatory cytokines that stimulate CD11b microglia,
further open the BBB, and stimulate chemotaxis, result-
ing in additional waves of inflammatory cell recruitment
and leakage of antibody and other plasma proteins into
the nervous system. Both CD11c and CD11b are mem-
bers of the integrin family expressed on neutrophils,
monocytes, NK cells, and activated T and B cells. The
activated C11b+ cells also contribute to the inflamma-
tory milieu by secreting T cell-activating factors such
as IL-12, IL-23, and toxic mediators such as nitric oxide
(NO) and oxygen radicals. Pathogenic T cells may not be
capable of producing or inducing tissue injury in the ab-
sence of the secondary leukocyte recruitment. For ex-
ample, in EAE mediated by adoptive transfer of mye-
lin-reactive encephalitogenic T lymphocytes, these
cells are among the first to infiltrate the CNS, but consti-
tute only a minor component of the total infiltrate in the
full-blown lesion. Despite being very effective in pre-
venting EAE, anti-CD4 antibody therapy has not been
successfully translated to humans (Lindsey et al.,
1994). CAMPATH-1H, which targets the CD52 antigen
present on lymphocytes and monocytes and causes
prolonged T cell depletion, showed substantial reduc-
tion in disability at 6 months in relapsing, but not sec-
ondary progressive, MS patients, perhaps due to the
suppression of ongoing inflammation in these patients
with active inflammatory disease (Coles et al., 2006).
The dramatic appearance of thyroid autoimmunity in
up to one-third of treated patients may be related to
the relaxation of T cell-mediated homeostatic mecha-
nisms induced by the anti-CD52 therapy (Goodnow
et al., 2005).
B cell activation and antibody responses appear to be
necessary for the full development of demyelination,
both in humans and in experimentally induced diseases
in animals. In most MS patients, an elevated level of
immunoglobulins synthesized intrathecally can be de-
tected in the cerebrospinal fluid. Although the specificity
of these antibodies is mostly unknown, anti-MBP spec-
ificities have been detected. Myelin-specific autoanti-
bodies have been detected bound to the vesiculated
myelin fragments, at least in some patients (Genain
et al., 1999; O’Connor et al., 2005). Recent data suggests
that antibodies specific for aquaporin-4 water channel,
a component of the dystroglycan protein complexlocated in astrocytic foot processes at the blood-brain
barrier, appear to be a biomarker of neuromyelitis op-
tica, an demyelinating disease that selectively affects
optic nerves and spinal cord and is considered an in-
flammatory condition that phenotypically resembles
a severe variant of MS (Lennon et al., 2005). Myelin-spe-
cific infiltrating B cells have been detected in the MS
brain, and in the CSF and brain parenchyma of affected
individuals there is an elevated frequency of clonally ex-
panded B cells with properties of postgerminal center
memory or antibody-forming lymphocytes (Baranzini
et al., 1999; Colombo et al., 2000; Corcione et al., 2004;
Owens et al., 1998; Smith-Jensen et al., 2000; Zhang
et al., 2005). Limited histological data suggests that B
cell differentiation, affinity maturation, and antibody se-
cretion occur primarily in the Virchow-Robin and menin-
geal spaces in MS, which may assume secondary lymph
node-like characteristics. Antibodies may participate in
myelin and axonal destruction through different mecha-
nisms such as opsonization, which facilitates phagocy-
tosis by macrophages; complement fixation; or stimula-
tion of antibody-dependent cell-mediated cytotoxicity
(ADCC) by binding to natural killer cells. The systemic
administration of B cell-depleting antibodies, such as
the humanized anti-CD20 monoclonal antibody Rituxi-
mab, is currently under evaluation in MS (Cree et al.,
2005; Cross and Stark, 2005), and positive results from
a phase 2 trial of Rituximab in relapsing-remitting MS
were recently reported. Rituximab causes transient de-
pletion of CD20+ pre-B and mature B cells, but not
stem or plasma cells. B cell depletion affects antibody
production, as well as B cell-mediated antigen presenta-
tion and activation of T cells and macrophages. Antago-
nism of B cell-activating factor of the tumor necrosis fac-
tor family (BAFF; also known as BLyS—B lymphocyte
stimulator), an important survival factor for peripheral
B cells, may be an alternative or an adjunct to Rituximab
therapy to enhance autoimmune B cell sensitivity to in-
trinsic tolerance mechanisms (Goodnow et al., 2005).
BAFF is primarily produced by radioresistant lymphoid
stromal cells, but a recent report suggests that it is
also produced in the brain by astrocytes and is upregu-
lated in MS lesions (Krumbholz et al., 2005). An anti-
BAFF antibody-based therapy is currently being tested
in systemic lupus erythematosus.
Modulating the Immune Response
Interferon b (IFNb) is a member of the type I interferon
family and, as a recombinant reagent, is the most fre-
quently prescribed therapeutic to control exacerbations
in relapsing-remitting MS. IFNb has pleiotropic effects,
including antagonism of IFN-g-mediated MHC upregu-
lation on antigen-presenting cells, alteration of the pro-
file of cytokine expression, modulation of apoptotic
pathways, and blockade of migration across endothelia.
Overall, IFNb has been shown to decrease clinical re-
lapses, reduce brain MRI activity, and possibly slow pro-
gression of disability. However, the effect of this treat-
ment is partial, and a substantial proportion of patients
are not responders. Therapy has been associated with
a number of adverse reactions, including flu-like symp-
toms, transient laboratory abnormalities, menstrual dis-
orders, increased spasticity, and dermal reaction. Fur-
thermore, the significance of long-term effects and
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mined. Baranzini and collaborators applied predictive
modeling tools to a longitudinal gene expression data-
set generated from MS patients treated with IFNb (Bar-
anzini et al., 2005). The analysis identified sets of gene
triplets whose expression, when tested before the initia-
tion of therapy, can predict favorable response with up
to 87% accuracy. It is noteworthy that the genes in the
top-scoring triplet were Caspase-2, Caspase-10, and
FLIP, three apoptosis-related molecules. Despite the
relatively high predictive accuracy of these models, the
functional link between genes and therapeutic effects
of this drug is still unclear.
Glatiramer Acetate, a polymer molecular mimic of a re-
gion of myelin basic protein, is another popular FDA-ap-
proved drug for MS. It affects the cytokine expression
pattern, but it also may saturate MHC molecules, pre-
venting efficient presentation of autoantigens by mono-
cytes and dendritic cells, and may induce active T cell
suppression against MBP (Farina et al., 2005). A new
generation of therapeutic synthetic peptides developed
based upon a better understanding of the molecular
structure of HLA molecules may be available for clinical
trials in the near future (Stern et al., 2005). Glucocorti-
coids are also potent inhibitors of antigen presentation
function. The chemotherapeutic drug cyclophospha-
mide is lympholytic and stimulates production of anti-in-
flammatory Th2 cytokines. Additional experimental ther-
apies focus on interference with antigen presentation to
encephalitogenic T cells (altered peptide ligands, intra-
venous antigens), induction of a Th2 response, T cell de-
pletion (anti-CD52 or anti TCRVb), blockade of adhesion
molecules, administration of anti-inflammatory cyto-
kines (IL-10, TGF-b), or neutralization of proinflamma-
tory cytokines (type IV phosphodiesterase inhibitors,
nerve growth factor, TNFR p55 Ig fusion protein, anti
TNF-aIgG1). Anti-TNF biologicals (monoclonal anti-
bodies and soluble receptor) have been extensively
and successfully used in rheumatoid arthritis, ankylos-
ing spondylitis, Crohn’s disease, and psoriasis. How-
ever, treatment of MS using lenercept, a TNFRp55-FC
construct, appears to have increased the frequency of
relapses. N-(3,4,-Dimethoxycinnamoyl) anthranilic acid
(3,4-DAA), an orally active synthetic derivative of the
amino acid tryptophan metabolite anthranilic acid, sup-
pressed proliferating of myelin specific T cells, inhibited
production of proinflammatory cytokines, and reversed
EAE paralysis; tryptophan metabolites may represent
a novel class of drugs to control inflammation in MS
(Platten et al., 2005).
Other approaches that have also proven effective in
blocking EAE, such as the use of statins, which inhibit
LFA-1, modulate MHC expression, and induce im-
mune-deviation, and antihistamines, which engage H1
receptors found in MS brain, may provide a new thera-
peutic strategy in MS for previously approved drugs. A
preliminary trial with statins has shown some degree
of efficacy (Vollmer et al., 2004). Similarly agonists for
the peroxisome proliferator-activated receptor-a and
angiotensin blockers may prove to be effective in MS
by inducing a cytokine shift from the proinflammatory
to the anti-inflammatory type (Feldmann and Steinman,
2005). Finally, it is possible to reverse ongoing paralysis
in the EAE model by using vectors encoding regulatorycytokines (or inflammatory cytokine inhibitors) or by tol-
erizing the immune system via injection of naked DNA
encoding myelin antigens together with DNA encoding
the cytokine IL-4. DNA vaccination has been taken into
the clinic for infectious disease and cancer, and trials
are now being organized to apply this approach to
autoimmune diseases, including MS (Feldmann and
Steinman, 2005).
A key but unresolved question is whether a single
mechanism of tissue damage is operative in MS, or
whether fundamentally distinct pathologies are present
in different cases. Heterogeneity has been observed in
terms of whether the inflammatory infiltrate is associ-
ated with the deposition of antibody and activation of
complement, and whether the target of the pathology
is the myelin sheath or the oligodendrocyte (Lucchinetti
et al., 2004). A recent study of very early MS lesions de-
scribes extensive apoptosis of oligodendrocytes as the
earliest structural change observed (Barnett and Pri-
neas, 2004). These changes, associated with microglial
activation but without other evident inflammatory infil-
trates, resembled ischemic changes. One critically im-
portant question is whether this heterogeneity reflects
fundamentally distinct mechanistic processes responsi-
ble for axonal damage, which may require overlapping
restorative strategies.
Neurodegeneration
The traditional neuropathological view of MS highlights
myelin loss as the key event leading to impaired propa-
gation of action potentials across the exposed region of
the axon and ensuing neurological deficits. However,
the early literature on MS already described substantial
axonal damage in active lesions (for an historical review
see Kornek and Lassmann, 1999). Contemporary high-
resolution histopathological studies reveal abundant
transected and dystrophic axons in sites of active in-
flammation and demyelination, and confirm that partial
or total axonal transection begins early in the disease
process (Bitsch et al., 2000; Ferguson et al., 1997; Trapp
et al., 1998). Axonal damage appears to take place in
every newly formed lesion, and the cumulative axonal
loss is considered now to be the reason for progressive
and irreversible neurological disability in MS (Neumann,
2003). Furthermore, reduced axonal density is also ob-
served in inactive and remyelinating lesions, cortical tis-
sue, and the normal-appearing white matter in the brain
and spinal cord. Pathological studies indicate that as
many as 70% of axons are lost from lateral corticospinal
tracts in patients with advanced paraparesis (Bjartmar
et al., 2000). Advanced MRI techniques increasingly pro-
vide a clinically useful and quantitative window into the
dynamic processes that result in progressive axonal
and neuronal loss over time. Examples include acceler-
ated rates of whole brain atrophy (Miller et al., 2002);
gradual worsening of focal (T1) lesions over time (Bag-
nato et al., 2003); reductions in the predominantly neuro-
nal/axonal marker n-acetyl aspartate (NAA) as assessed
by spectroscopy (Gadea et al., 2004); disruption of indi-
vidual white matter tracts, measured by diffusion tensor
imaging (Pagani et al., 2005); and evidence of plasticity
and altered functional connectivity by functional MRI
(Cader et al., 2006). Taken together, these in vivo
methods lend further support to the concept that axonal
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rological dysfunction that occurs in patients with MS
(Filippi and Rocca, 2005).
Knowledge of the mechanisms that trigger axonal in-
jury is far from complete and it is unclear whether demy-
elination is a prerequisite for axonal injury in MS. Mice
null for the glial cyclic nucleotide phosphodiesterase
(Cnp1) gene developed axonal swellings and neurode-
generation throughout the brain, leading to hydroceph-
alus and premature death, but the ultrastructure, period-
icity, and physical stability of myelin are apparently not
altered (Lappe-Siefke et al., 2003). On the other hand,
mice deficient for myelin associatge glycoprotein
(MAG) show late-onset axonal disease preceded by par-
anodal axon atrophy with reduced neurofilament spac-
ing, suggesting that an underlying disruption of myelin
can lead to a delayed and progressive axonal loss (Li
et al., 1994). Late-onset degeneration and disability
also occurs in proteolipid protein (PLP) null mice (Grif-
fiths et al., 1998). This also may be the case in human
MS (Garbern et al., 2002). Demyelination results in re-
duced support for the axons as well as redistribution
of ion channels, destabilization of axonal membrane
potentials, reduced excitability, and conduction block.
Axons can initially adapt and restore conduction, ex-
plaining remissions, but eventually distal and retrograde
degeneration occurs. Therefore, the early promotion of
remyelination and preservation of oligodendrocytes re-
mains an important therapeutic goal in MS. Another
source of functional CNS plasticity is the potential for
axonal remodeling independent of myelin integrity. In
a modified EAE model, spinal cord inflammation re-
sulted in extensive interneuron sprouting and connectiv-
ity associated with neurological recovery (Kerschen-
steiner et al., 2004).
In apparent contrast to the model of primary oligoden-
drocyte disease, some evidence suggests that axonal
damage is mediated directly by resident and invading in-
flammatory cells and their toxic soluble products, in par-
ticular microglia, macrophages, and CD8+ T lympho-
cytes. Indeed, neurons and axons express class I MHC
molecules, leaving them vulnerable to cytotoxic T cells
(Hoftberger et al., 2004). Axon-specific antibodies and
complement may also mediate axonal injury (Zhang
et al., 2005). A recent study in EAE provided convincing
evidence that axonal damage is associated with tau
phosphorylation and aggregation (Schneider et al.,
2004); the tau pathology was dependent on inflamma-
tion and could be partially prevented by early predniso-
lone treatment.
Liu et al. (2006) add to the growing body of evidence in
support of CNS-immune system cross-talk by demon-
strating a role for neurons in controlling the function of
inflammatory T cells within their immediate microenvi-
ronment. Neuron-T cell contact interaction results in
the local differentiation of T cells with a CD15+TGF-
b1+CTLA-4+Foxp3+ phenotype that suppresses prolif-
eration of encephalitogenic CD4+ T cells and progres-
sion of EAE. Transforming growth factor-b (TGF-b) is
a critical differentiation factor for the generation of these
regulatory T(reg) cells, through upregulation of Smad3
and IL-9. Remarkably, the T(reg) cells appear to be con-
verted from already-committed and activated encepha-
litogenic T cells in the CNS environment. Interleukin-6(IL-6) completely inhibits the generation of Foxp3(+)
T(reg) cells induced by TGF-b in peripheral tissues, but
together, IL-6 and TGF-b induce the differentiation of
pathogenic IL-17-producing cells from naive T cells. T-
helper-17 is a recently described CD4+ lineage distinct
from classical Th1/Th2 cells implicated in a growing
list of autoimmune diseases. TGF-b acts to upregulate
the IL-23 receptor, providing a positive autocrine signal
for expansion of Th17 cells (Bettelli et al., 2006; Mangan
et al., 2006). The overall cytokine milieu leads to the de-
velopment of mutually exclusive effector or regulatory
inflammatory pathways, which may be key to under-
standing how inflammation and infection is linked to
the development of CNS autoimmunity and neurode-
generation.
Resident microglia activated in the neuroinflammatory
process are likely to cause CNS tissue injury through the
release of mediators such as NO and oxygen radicals,
vasoactive amines, complement, proteases, cytokines,
and eicosanoids. Chronic ‘‘inactive’’ (e.g., noninflamma-
tory) MS lesions, and even normal-appearing white
matter in MS cases, are also characterized by activated
microglia and raised concentrations of NO (Lassmann,
2003). Excessive amounts of NO have been linked to
neurological symptoms as a result of direct injury to oli-
godendrocytes and axons (Acar et al., 2003; Smith,
2005). For example, demyelinated axons exposed
in vitro to NO experience significant conduction block,
whereas myelinated axons were affected only at higher
concentrations (Redford et al., 1997). Possible mecha-
nisms include the direct nitration of Na channels and in-
hibition of mitochondrial respiration, leading to reduced
ATP production. Aminoguanidine, a selective inhibitor of
NO, prevents the clinical development of EAE and re-
duces inflammation and demyelination (Cross et al.,
1994). On the other hand, mice genetically deficient for
NOS2A were shown to be highly susceptible to EAE in-
duced by immunization with myelin oligodendrocyte
glycoprotein (MOG) (Sahrbacher et al., 1998), consistent
with the presence of complex and systemic regulatory
networks in autoimmune demyelination.
NO also mediates the excitatory effect of glutamate,
and the excess of glutamate released by microglia and
macrophages, accompanied by a decrease in glutamate
intake and metabolism, activates a-amino-3-hydroxy-5-
methil-4-isoxazolp-propionic acid (AMPA), which is
highly toxic to oligodendroglial cells and neurons.
Blockade of AMPA-responsive glutamate receptors
with AMPA antagonists ameliorates neurological se-
quelae in EAE, increases oligodendrocyte survival, and
reduces dephosphorylation of neurofilament H, an indi-
cator of axonal damage. Drugs affecting microglial func-
tion, such as hydroxymethyl-glutaryl coenzyme A
(HMG-coA) reductase inhibitors, or agonists of peroxi-
some proliferator-activated receptor (PPAR) a, such as
gemfibrozil, ameliorate EAE and are now being tested
in MS (Platten and Steinman, 2005). Another source
of glutamate release is the astrocyte, through a Ca-
regulated exocytosis-like process (Bezzi et al., 2004). In-
terestingly, glutamate release appears to follow the
activation of the CXCR4 by the chemokine stromal
cell-derived factor 1 (SDF-1) and is followed by rapid re-
lease of TNF-a by the microglia, which can lead to neu-
ronal death by apoptosis (Bezzi et al., 2001).
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sion and function in oligodendrocytes (Salter and Fern,
2005; Karadottir et al., 2005). Expression was detected
in several regions of the brain and at various develop-
mental stages, but appears limited to the oligodendro-
cyte processes, explaining why previous studies that
have focused on the somata failed to detect these re-
ceptors. This represents an unexpected and novel find-
ing since glutamate was thought to activate exclusively
the AMPA and kainate receptors in oligodendrocytes.
Under pathological conditions, NMDAR stimulation
may provoke oligodendrocyte injury. Using an in vitro
model mimicking ischemia, Salter and Fern (2005) dem-
onstrate that glutamate activation of the NMDAR and the
subsequent intracellular Ca2+ overload cause the loss of
the oligodendrocyte processes. Moreover, the selective
NMDAR antagonist MK801 was able to confer protec-
tion in this model. Karadottir et al. (2005) simulated is-
chemia in brain slices by energy deprivation, causing
the development of an inward current in the oligoden-
drocytes, partly evoked by the NMDAR. Altogether, the
data shows Ca2+ dependence in the NMDAR-mediated
oligodendrocyte injury, and indicates that Ca2+ influx
can affect the cytoskeletal element within the pro-
cesses, which will determine their stabilization or retrac-
tion. The unusual subunit composition of these recep-
tors, which include primarily the NR1, NR2C, and
NR3A subunits, suggest that novel selective NMDA re-
ceptor antagonists can be developed devoid of the
side effects characteristic of the existing ones.
Once the molecular mechanism of axonal damage is
triggered, ion fluxes, mitochondrial dysfunction, and ac-
tivation of proteases culminate in degradation of cyto-
skeletal proteins and axonal disintegration (Dutta
et al., 2006). The early influx of Na+ and Ca2+ ions into
the axoplasm as a result of channel exposure or upregu-
lation is highly excitotoxic and leads to interrupted axo-
nal transport and accumulation of proteins, such as
amyloid precursor protein, N-type voltage-gated Ca2+
channels, nonphosphorylated neurofilament proteins,
and metabotropic glutamate receptors (Peterson et al.,
2005). Limited data suggest that neuronal cell death by
apoptosis could also have a significant contribution to
neurodegeneration in MS (Cid et al., 2002).
Promoting Remyelination and Repair
A characteristic of many MS lesions is the presence of
large numbers of NG2-positive oligodendrocyte precur-
sor cells (OPC) as well as PLP-positive preoligodendro-
cytes that survive the acute inflammatory onslaught
(Chang et al., 2000). These arrested oligodendrocytes
extend processes to the vicinity of surviving axons,
but fail to remyelinate. The development of practical
strategies to promote reconstitution of functional myelin
from this locally available precursor pool represents an
obvious strategy for restorative therapy (for a recent re-
view, see Dubois-Dalcq et al., 2005). Following injury, ol-
igodendrocyte-mediated remyelination is dependent on
the transcription factor Olig-1, which represents an ex-
cellent target for therapy (Arnett et al., 2004). Inflamma-
tory signals derived from macrophages (Kotter et al.,
2005) and lymphocytes (Bieber et al., 2003; Foote and
Blakemore, 2005) also influence the capacity for remye-
lination. Remyelination is also enhanced by cytokinessuch as IL-1b (Vela et al., 2002), either directly or indi-
rectly via stimulation of IGF-1 by astrocytes, macro-
phages, or monocytes (Mason et al., 2001). Growth fac-
tors, such as platelet-derived growth factor (PDGF) or
FGF-2, have been shown to expand OPCs (Frost et al.,
2003; Woodruff et al., 2004). Negative effects on remye-
lination can also result from the cytokine milieu present
in a chronic inflammatory or highly gliotic environment
(Diemel et al., 2004; Foote and Blakemore, 2005), high-
lighting the complexity of the interactions. Furthermore,
it is possible that the demyelinated axon is unreceptive
to remyelination due to intrinsic axolemmal changes,
possibly including expression of inhibitory cell surface
molecules such as polysialylated-neural cell adhesion
molecule (Charles et al., 2000), changes in membrane
caliber, neurofilament fragmentation, or energy failure
(Dutta et al., 2006).
Human OPC engrafted in a myelin-deficient (shiverer)
mouse were able to restore myelination (Windrem et al.,
2004), raising hope that a similar strategy might be use-
ful in MS. Schwann cells represent another potential
source of cell replacement therapy (Bachelin et al.,
2005). In EAE, systemically injected neurospheres pro-
tected animals from paralysis; however, these beneficial
effects appeared to be mediated by induction of immu-
noregulatory networks that reduced tissue damage,
and not primarily by promotion of remyelination (Plu-
chino et al., 2005). The failure of adequate remyelination
in MS appears to result from an inhospitable environ-
ment within the plaque or lack of sufficient signals for
extensive myelination (Setzu et al., 2006), rather than
a lack of myelin precursor cells. Therefore, it seems
unlikely that therapy with nonengineered precursor
cells will provide, on its own, a sufficient stimulus for re-
myelination. More likely, engineered cells could be used
to deliver therapeutic molecules to areas of tissue
damage.
The concept that progressive (‘‘slow-burning’’) axonal
loss occurring over time in demyelinated lesions is re-
sponsible for late chronic disability is supported by his-
tologic studies (Bjartmar et al., 2000; Kornek et al., 2000)
and by serial MRI studies revealing accelerated atrophy
over time (Losseff et al., 1996). As summarized above,
high concentrations of NO may contribute to mitochon-
drial dysfunction and raised intracellular Na+ and Ca2+
(Smith et al., 2001). Consequent to demyelination, the
coexpression of Na+ channels with the Na+/Ca2+ ex-
changer along the length of the naked axon could further
contribute to Na+ influx and raised intracellular Ca2+
(Craner et al., 2004). Axonal protection strategies using
Na+ channel inhibitors, either phenytoin (Lo et al.,
2003a) or flecainide (Bechtold et al., 2004), have shown
potential as neuroprotective agents in preclinical EAE
models, and human trials are underway with phenytoin
and lamotrigine.
With the aid of high-powered laboratory technologies,
we are now in a position to define the full array of genes,
molecules, and pathways operating in MS. This informa-
tion will likely provide a reliable conceptual model of
pathogenesis and lead to novel curative strategies.
This goal can only be achieved if sufficient knowledge
exists to distinguish disease variants, reliably classify
therapeutic outcomes, and capture key individual ge-
netic, medical, and molecular profiling variables.
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